{
    "address1": "60 Leveroni Court",
    "city": "Novato",
    "state": "CA",
    "zip": "94949",
    "country": "United States",
    "phone": "415 483 8800",
    "website": "https://www.ultragenyx.com",
    "industry": "Biotechnology",
    "industryDisp": "Biotechnology",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",
    "fullTimeEmployees": 1311,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Dr. Emil D. Kakkis M.D., Ph.D.",
            "age": 62,
            "title": "Founder, Pres, CEO & Director",
            "yearBorn": 1960,
            "fiscalYear": 2022,
            "totalPay": 1366354,
            "exercisedValue": 0,
            "unexercisedValue": 1888758
        },
        {
            "maxAge": 1,
            "name": "Mr. John Richard Pinion II",
            "age": 56,
            "title": "Chief Quality Operations Officer & Exec. VP of Translational Sciences",
            "yearBorn": 1966,
            "fiscalYear": 2022,
            "totalPay": 806193,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Erik  Harris",
            "age": 51,
            "title": "Exec. VP & Chief Commercial Officer",
            "yearBorn": 1971,
            "fiscalYear": 2022,
            "totalPay": 848237,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Theodore A. Huizenga",
            "age": 51,
            "title": "Sr. VP, Corp. Controller & Principal Accounting Officer",
            "yearBorn": 1971,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Dennis Karl Huang",
            "age": 57,
            "title": "Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP",
            "yearBorn": 1965,
            "fiscalYear": 2015,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Danielle  Keatley",
            "title": "Sr. Director of Investor Relations & Corp. Communications",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Karah Herdman Parschauer J.D.",
            "age": 44,
            "title": "Chief Legal Officer & Exec. VP",
            "yearBorn": 1978,
            "fiscalYear": 2018,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Ernie W. Meyer",
            "age": 58,
            "title": "Chief HR Officer & Exec. VP",
            "yearBorn": 1964,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Thomas R. Kassberg",
            "age": 62,
            "title": "Chief Bus. Officer & Exec. VP",
            "yearBorn": 1960,
            "fiscalYear": 2019,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Vimal  Srivastava",
            "age": 57,
            "title": "Sr. VP of Bus. Devel. & Alliance Management",
            "yearBorn": 1965,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 1,
    "boardRisk": 1,
    "compensationRisk": 5,
    "shareHolderRightsRisk": 7,
    "overallRisk": 3,
    "governanceEpochDate": 1690848000,
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 36.97,
    "open": 36.97,
    "dayLow": 36.97,
    "dayHigh": 38.565,
    "regularMarketPreviousClose": 36.97,
    "regularMarketOpen": 36.97,
    "regularMarketDayLow": 36.97,
    "regularMarketDayHigh": 38.565,
    "payoutRatio": 0.0,
    "beta": 0.854173,
    "forwardPE": -5.7352495,
    "volume": 405644,
    "regularMarketVolume": 405644,
    "averageVolume": 555333,
    "averageVolume10days": 514720,
    "averageDailyVolume10Day": 514720,
    "bid": 37.86,
    "ask": 38.86,
    "bidSize": 800,
    "askSize": 1200,
    "marketCap": 2710132736,
    "fiftyTwoWeekLow": 33.36,
    "fiftyTwoWeekHigh": 54.98,
    "priceToSalesTrailing12Months": 6.7272987,
    "fiftyDayAverage": 42.5592,
    "twoHundredDayAverage": 42.9507,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "enterpriseValue": 2183560704,
    "profitMargins": -1.78907,
    "floatShares": 62628052,
    "sharesOutstanding": 71488600,
    "sharesShort": 3512722,
    "sharesShortPriorMonth": 3964604,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.049099997,
    "heldPercentInsiders": 0.04665,
    "heldPercentInstitutions": 0.98579,
    "shortRatio": 6.58,
    "shortPercentOfFloat": 0.0514,
    "impliedSharesOutstanding": 71488600,
    "bookValue": 1.806,
    "priceToBook": 20.99114,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "netIncomeToCommon": -720739008,
    "trailingEps": -10.62,
    "forwardEps": -6.61,
    "pegRatio": 0.05,
    "enterpriseToRevenue": 5.42,
    "enterpriseToEbitda": -3.346,
    "52WeekChange": -0.22805947,
    "SandP52WeekChange": 0.09306288,
    "exchange": "NMS",
    "quoteType": "EQUITY",
    "symbol": "RARE",
    "underlyingSymbol": "RARE",
    "shortName": "Ultragenyx Pharmaceutical Inc.",
    "longName": "Ultragenyx Pharmaceutical Inc.",
    "firstTradeDateEpochUtc": 1391178600,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "b052b015-0bd3-3428-acad-e3223ac2e5e2",
    "messageBoardId": "finmb_117471985",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 37.91,
    "targetHighPrice": 140.0,
    "targetLowPrice": 47.0,
    "targetMeanPrice": 89.85,
    "targetMedianPrice": 87.0,
    "recommendationMean": 1.7,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 20,
    "totalCash": 551980992,
    "totalCashPerShare": 7.722,
    "ebitda": -652508032,
    "totalDebt": 25729000,
    "quickRatio": 2.557,
    "currentRatio": 2.873,
    "totalRevenue": 402856000,
    "debtToEquity": 19.94,
    "revenuePerShare": 5.725,
    "returnOnAssets": -0.31951,
    "returnOnEquity": -1.78599,
    "grossProfits": -370780000,
    "freeCashflow": -391286240,
    "operatingCashflow": -458715008,
    "revenueGrowth": 0.212,
    "grossMargins": -0.92345,
    "ebitdaMargins": -1.6197,
    "operatingMargins": -1.6699699,
    "financialCurrency": "USD",
    "trailingPegRatio": null,
    "parent_etfs": [
        "GNOM"
    ]
}